Related Experiment Video
Updated: Jul 20, 2026
07:44
Localization of the Locus Coeruleus in the Mouse Brain
Published on: March 7, 2019
Low-dose methylphenidate actions on tonic and phasic locus coeruleus discharge
David M Devilbiss1, Craig W Berridge
1Department of Psychology, University of Wisconsin, Madison, WI 53706, USA. ddevilbiss@wisc.edu
The Journal of Pharmacology and Experimental Therapeutics
|September 19, 2006
Summary
Low doses of methylphenidate (MPH) modestly suppress locus coeruleus (LC) neuronal activity in rats, impacting both tonic and phasic firing patterns. These subtle changes in LC discharge may contribute to the therapeutic effects of ADHD medications.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Methylphenidate (MPH) is a key psychostimulant for treating attention deficit hyperactivity disorder (ADHD).
- The locus coeruleus (LC)-norepinephrine system is implicated in the therapeutic mechanisms of stimulants in ADHD.
- LC neurons exhibit distinct tonic and phasic firing modes, influencing behavior and cognition.
Purpose of the Study:
- To investigate the effects of low, clinically relevant doses of MPH on LC neuronal tonic and phasic discharge.
- To determine if MPH administration route (oral vs. intraperitoneal) affects its impact on LC activity.
Main Methods:
- Electrophysiological recordings of LC neuronal discharge in halothane-anesthetized rats.
- Administration of varying low doses of MPH via oral and intraperitoneal routes.
- Analysis of tonic discharge rates and phasic response characteristics, including signal-to-noise ratios.
Main Results:
- MPH induced a dose-dependent suppression of both tonic and phasic LC neuronal discharge.
- Lower MPH doses showed modest suppression, with greater sensitivity observed in evoked phasic discharge compared to tonic activity.
- MPH altered the signal-to-noise ratio of phasic responses, suppressing excitatory components and enhancing inhibitory components.
- Comparable effects were observed regardless of MPH administration route.
Conclusions:
- Low-dose MPH exerts a modest suppressive effect on LC neuronal activity.
- Evoked LC discharge appears more sensitive to low-dose MPH than tonic discharge.
- These findings suggest that subtle alterations in LC discharge, alongside increased catecholamine efflux in brain regions like the prefrontal cortex, may underlie the cognitive and behavioral effects of MPH in ADHD treatment.
Related Concept Videos
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:28Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:22CNS Stimulants: Psychedelic Agents
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...